Cardiac Myosin Binding Protein-C Autoantibodies Are Potential Early Indicators of Cardiac Dysfunction and Patient Outcome in Acute Coronary Syndrome

Thomas L. Lynch, Diederik W.D. Kuster, Beverly Gonzalez, Neelam Balasubramanian, Nandini Nair, Sharlene Day, Jenna E. Calvino, Yanli Tan, Christoph Liebetrau, Christian Troidl, Christian W. Hamm, Ahmet Güçlü, Barbara McDonough, Ali J. Marian, Jolanda van der Velden, Christine E. Seidman, Gordon S. Huggins, Sakthivel Sadayappan

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)


The degradation and release of cardiac myosin binding protein-C (cMyBP-C) upon cardiac damage may stimulate an inflammatory response and autoantibody (AAb) production. We determined whether the presence of cMyBP-C-AAbs associated with adverse cardiac function in cardiovascular disease patients. Importantly, cMyBP-C-AAbs were significantly detected in acute coronary syndrome patient sera upon arrival to the emergency department, particularly in ST-segment elevation myocardial infarction patients. Patients positive for cMyBP-C-AAbs had reduced left ventricular ejection fraction and elevated levels of clinical biomarkers of myocardial infarction. We conclude that cMyBP-C-AAbs may serve as early predictive indicators of deteriorating cardiac function and patient outcome in acute coronary syndrome patients prior to the infarction.

Original languageEnglish
Pages (from-to)122-131
Number of pages10
JournalJACC: Basic to Translational Science
Issue number2
Publication statusPublished - 1 Apr 2017


  • acute myocardial infarction
  • autoantibodies
  • cardiac myosin binding protein-c
  • cardiomyopathy

Cite this